The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved the use of Moderna’s covid-19 vaccine Spikevax on children aged 12-17, according to an EMA press release.
The committee has approved the vaccine following studies involving 3,732 children in this age group, which showed that its efficacy and side effects much resembled those seen in adults who have received the vaccine.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.